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Background: Small interfering RNA (siRNA) has attracted attention in the field of nucleic acid medicine as a RNA
interference (RNAi) application that leads to gene silencing due to specific messenger RNA (mRNA) destruction.
However, since siRNA is unstable in blood and unable to cross the cell membrane, encapsulation of siRNA into a
carrier is required.
Results: In this study, we used a carrier that combined ZHER2-displaying bio-nanocapsule (derived from hepatitis B
virus surface antigen) and liposomes in a complex in order to investigate the feasibility of effective and target-cell
-specific RNAi applications. As a result, by observing RNAi only in HER2-expressing breast cancer cells, using our
proposed methodology, we successfully demonstrated target-cell-specific delivery and effective function expression
of siRNA.
Conclusions: These findings show that, in the field of nucleic acid medicine, ZHER2-BNC/LP can be a useful carrier
for siRNA delivery, and could also become a useful tool for gene silencing and to accomplish protein knock-down.
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RNA interference (RNAi) is expected to become a new
approach in treating a variety of diseases, such as virus
infection, cancer and neurodegenerative diseases, owing
to specific and effective gene silencing [1,2]. The mech-
anism of RNAi involves double-stranded RNA injected
into cells that are first cut into short RNA (small inter-
fering RNA (siRNA)), 21–23 bp long, using ribonuclease
(RNase) III enzyme that is referred to as the Dicer.
The duplex siRNA forms a RNA-induced silencing com-
plex (RISC), which contains an endonuclease and an
Argonaute protein. The siRNA duplex is dissociated into
unwound single-stranded RNA using an ATP-dependent
helicase; therefore, the RISC with an antisense strand
against target messenger RNA (mRNA) leads to RNA* Correspondence: akondo@kobe-u.ac.jp
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reproduction in any medium, provided the ordestruction and results in a downregulation of gene ex-
pression [3-6]. Although the use of siRNA is a promising
approach for nucleic acid medicine, several problems re-
main with respect to its in vivo use, such as an inability
to cross membranes, an instability in the blood, and a
lack of ability to specifically target abnormal cells [1,7].
A bio-nanocapsule (BNC) is a hollow nano particle
composed of the L protein of the hepatitis B virus
(HBV), surface antigen (HBsAg), and a lipid bilayer. The
BNC exhibits a reliable safety profile due to being
viral-genome-free and shows high specificity for human
hepatocytes and a high transfection efficiency that is
equivalent to the original HBV [8]. Therefore, the BNC
has been studied as a carrier for the delivery of drugs
and genes [9].
Previously, we and other researchers succeeded in al-
tering the cell-specificity of BNCs by deleting the
hepatocyte-specific recognition site (located in the preS
region) in the L protein and inserting binding moleculesral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Nishimura et al. Journal of Nanobiotechnology 2013, 11:19 Page 2 of 9
http://www.jnanobiotechnology.com/content/11/1/19with the ability to target other cells [10]. For example,
we have displayed the ZHER2 affibody molecule, which
can specifically recognize human epidermal growth fac-
tor receptor 2 (HER2) expressed in breast and ovarian
cells, as ligand on the surface of BNC (ZHER2-BNC).
Affibody molecules (58 a.a.; 7 kDa) are new class of
binding proteins derived from the Z domain of staphylo-
coccal protein A and are consisted of three α-helices.
Random mutation of 13 amino acid residues in N-
terminal two helices can alter the recognition ability of
affibody [11]. This led to successful alteration in the spe-
cificity of a BNC from hepatocytes to HER2 receptor ex-
pressing cells such as those found in breast and ovarian
cancer [12].
Additionally, the fusion of medicinal proteins [13] and
an electroporation [9] and a BNC/liposome (BNC/LP)
conjugation [14] have been previously reported as
methods used for encapsulating drugs and genes into
BNCs. In particular, the BNC/LP conjugation method
has succeeded in encapsulating various-sized materials
including low-molecular compounds, genes and proteins
into BNC/LP complex carriers [15,16]. The complex car-
riers are formed by fusing BNCs to the surface of LPs, in
which target materials have been pre-encapsulated. By
changing the phospholipid composition of LPs or the
types of BNCs, a variety of characteristic features are
granted to the BNC/LP complex carriers. For example,
anionic phospholipid can avoid non-specific binding to
non-target cells [16]; pH-responsive phospholipids (1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine; DOPE) pro-
vide the ability for endosomal escape [16]; and, affibody-
displaying BNCs can alter cell-specificity [12]. By using
this method, we previously constructed ZHER2-BNC/LP
complex carriers and succeeded in the specific and func-
tional delivery of proteins for HER2-expressing breast can-
cer cells [16].
In the present study, to overcome the problems in
siRNA therapy, we tried the specific delivery of siRNA
into target cancer cells by using the BNC/LP complex as
the carrier (Figure 1). To facilitate the evaluation of
RNAi, an siRNA that would inhibit GFP expression was
selected. We describe how the ZHER2-BNC/LP complex
can specifically deliver siRNA into HER2-expressing




BNCs were prepared from Saccharomyces cerevisiae
AH22R- harboring either of the plasmids pGLDsLd50-
ZHER2 or pGLDsLd50-ZWT [12], as described previ-
ously [8]. Briefly, yeast cells transformed with
pGLDsLd50-ZHER2 or pGLDsLd50-ZWT by the sphero-
plast method were cultured and disrupted with glassbeads, the crude extract was precipitated with poly-
ethylene glycol (PEG) 6000 and subjected to cesium
chloride (CsCl) isopycnic ultracentrifugation and
sucrose density gradient ultracentrifugation, and then
the purified BNCs were obtained after freeze-drying
in the presence of 5% sucrose. Liposome (LP),
COATSOME EL-01-D (1,2-dioleoyl-sn-glycero-3-phos
phoethanolamine (DOPE) : CHOL :O,O’-ditetradecanoyl-
N-(α-trimethylammonioacetyl) diethanolamine chloride
(DC6-14) = 0.75 : 0.75 : 1.00 (μmol/vial)) was purchased
from NOF (Tokyo, Japan). Silencer® GFP (eGFP) siRNA and
Lipofectamin™ RNAiMAX Reagent was purchased from
Invitrogen Life Technologies (Carlsbad, CA, USA). Amicon®
Ultra-0.5 mL Centrifugal Filter Units (100,000 NMWL)
were purchased from Merck Millipore (Massachusetts,
USA). siRNA Ladder Marker was purchased from
Takara Bio (Shiga, Japan). Gibco® Fetal bovine serum
(FBS) and an L-glutamine and Molecular Probes® LIVE/
DEAD® viability/cytotoxicity assay kit were purchased
from Invitrogen Life Technologies. RPMI 1640 medium
and Dulbecco’s modified Eagle medium (DMEM) were
purchased from Nacalai Tesque (Kyoto, Japan). Blasticidin
was purchased from InvivoGen (San Diego, CA, USA).
Preparation of BNC/LP complex and incorporation of
siRNA
Complex carriers of ZHER2-BNC and ZWT-BNC and LP,
in which siRNA was incorporated, were prepared by re-
ferring to the previously described BNC/LP conjugation
method with some modifications [14]. Freeze-dried LPs
(COATSOME EL-01-D, 1.5 mg) were dissolved in dis-
tilled water (1 ml) containing 200 nM of siRNA. After
incubation for 1 h at room temperature, LP-mixing
siRNA (100 μl) was added to freeze-dried ZHER2-BNC or
ZWT-BNC (50 μg as protein) and incubated at room
temperature for 1 h to form BNC/LP complexes. The re-
sultant complex carriers were named ZHER2-BNC/LP
and ZWT-BNC/LP.
Measuring the zeta potential and diameter of particles
The zeta potentials of LPs and a BNC/LP complex were
determined using a Zetasizer Nano ZS (Malvern Instru-
ments, Worcestershire, UK), following the manufac-
turer’s procedure.
Evaluation of siRNA encapsulation efficiency
The siRNA solution (200 nM) and the mixture of
ZHER2-BNC/LP and siRNA were quadruply concentrated
using Amicon® Ultra-0.5 centrifugal filter units with a
100-kDa cutoff. Native (non-denaturing) polyacrylamide
gel electrophoresis (native-PAGE) was performed
(60 mA, Tris/glycine buffer) to determine free-siRNA,
which could be never contained in the ZHER2-BNC/LP
complex. After staining the gel with ethidium bromide,










Figure 1 Schematic illustration for conjugate formation of ZHER2-BNC/LP complex containing siRNA.
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an ImageQuant LAS 4000 (GE Healthcare, Buckingham-
shire, England), following the manufacturer’s procedure
and by the following formula: Vlane3/Vlane1 × 100%. Vlane1
and Vlane3 were denoted as volume of band detected
from quantitative imaging of the gel.
Cell culture
To evaluate and quantify the RNAi efficacy, we used the
cells that constitutively express GFP. SKBR3 cells (hu-
man breast carcinoma) were maintained in RPMI 1640
medium supplemented with 10% (v/v) FBS and 5 μg/ml
Blasticidin at 37°C in 5% CO2. HeLa cells (human cer-
vical carcinoma) were maintained in DMEM medium
supplemented with 10% FBS and 5 μg/ml Blasticidin at
37°C in 5% CO2.
Flow cytometric evaluation of RNAi and cell viability
Approximately 1 × 105 SKBR3 and HeLa cells were
seeded in 12-well plates and incubated 37°C for 24 h.
After washing with serum-free medium, the required
volumes of the complex carriers and LPs containing
siRNA were added to the medium, and the volume was
adjusted to 1 ml. Cells were incubated for 4 h, and then
were washed twice with serum-free medium and cul-
tured with FBS-containing medium for 44 h.
siRNA was also directly transfected to cells with
RNAiMAX, following the manufacturer’s procedure.
Briefly, the required volumes of 50 mM siRNA and 2 μl
of RNAiMAX were added to 200 μl of serum-free
medium in 12-well plates, and the medium wasincubated for 20 min at room temperature. Then, 1 ml
of serum-free medium containing cells (1 × 105) was
added to the 12-well plates. Cells were incubated for 4 h,
washed twice with serum-free medium, and cultured
with FBS-containing medium for 44 h.
To quantify RNAi efficacy, green fluorescence was
detected and the decrement of GFP-expressing cells was
counted. To quantify cell viability, red fluorescence was
detected and the dead cells stained with EthD-1 were
counted. The EthD-1 staining was performed using a
LIVE/DEAD® viability/cytotoxicity assay kit according to
the manufacturer’s instructions. Cells were suspended
into a sheath solution and subjected to a BD FACSCanto
II flow cytometer equipped with a 488-nm blue laser
(BD Biosciences, San Jose, CA, USA). The green and red
fluorescence signals were collected through 530/30 and
585/42-nm band-pass filters, respectively. The data were
analyzed using BD FACSDiva software v5.0 (BD
Biosciences).
Microscopic observation of GFP-expressing cells treated
with siRNA
The introduction of siRNA basically followed the above-
described procedure with some modifications: 12-well
plates were changed to 35 mm glass bottom dishes; the
final concentration of siRNA in the medium was fixed to
25 nM; and, the total volume of medium was adjusted to
2 ml.
Cells were observed using a LSM 5 PASCAL laser
scanning confocal microscope (Carl Zeiss, Oberkochen,
Germany) equipped with a 63-fold oil immersion
Table 1 The sizes and zeta potentials of ZHER2-BNCs only,
LPs only, LPs containing siRNA and ZHER2-BNC/LP
complex containing siRNA
Carrier Diameter [nm] Zeta potential [mV]
ZHER2-BNC 25 ± 1.3 −23.7 ± 2.4
LP 155 ± 11.3 3.9 ± 1.8
LP containing siRNA 134 ± 13.0 1.4 ± 2.9
ZHER2-BNC/LP containing siRNA 97 ± 18.0 −5.1 ± 1.2
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an argon laser and emission collection using a 505-nm
long pass filter.
Results
Target cell-specific RNAi with ZHER2-BNC/LP
First, to examine the specific delivery of siRNA, we used
HER2-expresing SKBR3 cells (human breast carcinoma)
as target cells [17]. HER2-non-expressing HeLa cells (hu-



































Figure 2 The DLS analyses of ZHER2-BNC, LP, LP containing siRNA and[18]. To evaluate and quantify the RNAi efficacy, we used
the cells constantly expressing the chromosomally-
integrated GFP. RNAiMAX, LPs and ZHER2-BNC/LP were
tested to deliver silencer GFP siRNA which can specifically
interfere with the expression of GFP. The diameter, zeta
potential and particle size distribution of each particle are
shown in Table 1 and Figure 2. Since the different particle
size distributions between ZHER2-BNC and LP containing
siRNA were integrated into indistinguishable single distri-
bution, it seemed that nearly every ZHER2-BNC and LP
was conjugated (Figure 2). Because ZHER2-BNC has mem-
brane fusion domains derived from L protein [14], it
would appear that the lipid-lipid conjugation between
ZHER2-BNC and LP has occurred efficiently. The particle
size distribution of ZHER2-BNC/LP remained the same
after incubation for 10 days at 4°C (data not shown).
Second, to evaluate encapsulation efficiency of siRNA
into ZHER2-BNC/LP, we analyzed free-siRNA by native-
PAGE (Figure 3). Since the siRNA contained in ZHER2-



















Figure 3 Analysis of siRNA encapsulation efficiency by native-
PAGE. Lane 1 and lane 2 show quadruple concentrated solution of
siRNA (200 nM) and its waste solution, respectively. Lane 3 and lane
4 show quadruple concentrated mixture of ZHER2-BNC/LP containing
siRNA and its waste solution, respectively.
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mer band after electrophoresis. By comparing the de-
gree of reduction between the band in lane 1 (siRNA
solution without LP) and that in lane 3 (free-siRNA
from ZHER2-BNC/LP), the encapsulation efficiency of
siRNA into ZHER2-BNC/LP could be estimated. As the
result of measurement for the degree of siRNA reduc-
tion using ImageQuant LAS 4000, encapsulation effi-
ciency of siRNA was 94.4%. This demonstrated that it
was possible to encapsulate siRNA efficiently into
ZHER2-BNC/LP.
After 48 h of incubation, the efficacies of RNAi de-
pending on the additive concentration of siRNA were
determined by measuring the cell population rates miss-
ing GFP fluorescence. The efficacies of RNAi for HER2-
expressing SKBR3 cells and HER2-non-expressing HeLa
cells are shown in Figures 4A and 4B, respectively. In
the case of using RNAiMAX (white bars), RNAi was ob-
served even at lower concentrations of siRNA (1 nM~)
in both SKBR3 and HeLa cells. This indicated that the
transfection reagent never showed specificity to the tar-
get cells, although it has the ability for high transfection
efficiency. The LPs without ZHER2-BNC (gray bars) alsotriggered RNAi in both cells, similar to the case of
RNAiMAX. The zeta potential of LPs encapsulating
siRNA showed a positive charge (Table 1), suggesting
that it was bound to cells non-specifically due to an elec-
trostatic interaction. However, the ZHER2-BNC/LP com-
plex displayed the specific effect of RNAi only for
HER2-expressing SKBR3 cells (Figures 4A and 4B; black
bars). Furthermore, the RNAi efficacies of ZHER2-BNC/
LP that were >10 nM were equal to that of RNAiMAX.
This result indicates that the siRNA delivery with ZHER2-
BNC/LP was HER2-expressing breast cancer cell-
specific siRNA delivery, and that it led to an effective ex-
pression of the RNAi function.
Viability of cells treated with ZHER2-BNC/LP
To evaluate the biocompatibility of each carrier
containing siRNA, we measured cell survival rates with
a type of EthD-1 that permits the detection of dead cells
under the progression of RNAi. The cell viabilities of
SKBR3 (Figure 5A) and HeLa (Figure 5B) were similar,
but slightly different for each carrier. The slight decrease
in the viability of LPs (gray bars) might have been due to
the excess non-specific binding of phospholipids to the
cell membrane. A significant decrease in viability was
not observed for ZHER2-BNC/LP (black bars). This result
suggests that ZHER2-BNC/LP was non-toxic to cells.
Confirmation of the occurrence of siRNA-specific and
affibody-dependent RNAi
To confirm whether the inhibition of protein synthesis
was really led by the action of siRNA, we used the
siRNA that never inhibits GFP expression (negative
siRNA) (Figure 6). We added 25 nM carriers containing
negative siRNA to SKBR3 and HeLa cells. As a result,
RNAi was never detected in the presence of any of these
carriers (Figures 6A and 6B). This result clearly shows
that the decrement of GFP-expressing cells in Figure 4
was surely guided by siRNA-specific action.
To establish the validity of using ZHER2-BNC to grant
cell-specificity, we compared ZHER2-BNC/LP with ZWT-
BNC/LP using the ZWT (Z domain)-displaying BNC
without HER2 recognition ability to form the BNC/LP
complex (Figure 7). Each complex carrier with siRNA
was added to SKBR3 and HeLa cells (final conc. 25 nM
as siRNA), and the rates of RNAi and cell viability were
evaluated after 48 h of incubation. As a result, ZHER2-
BNC/LP triggered SKBR3-specific RNAi, whereas ZWT-
BNC/LP did not invoke RNAi in either cell. Thus, the
importance of the affibody-displaying BNC for specific
siRNA delivery was confirmed.
Microscopic observation of GFP interference
To visually confirm the inhibition of GFP synthesis
by RNAi, we treated SKBR3 and HeLa cells with
























































Figure 4 Quantification of RNAi in HER2-positive SKBR3 (A) and HER2-negative HeLa (B) cells treated by siRNA combined with
RNAiMAX (white bars), LPs (gray bars) and ZHER2-BNC/LP complex (black bars). The GFP expressions of the cells were analyzed using a flow
cytometer and results are expressed as a percentage of the GFP-expressing cellular quantity in untreated controls. The x-axis represents the final
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Figure 5 Cell survival rates of HER2-positive SKBR3 (A) and HER2-negative HeLa (B) cells treated by siRNA combined with RNAiMAX
(white bars), LPs (gray bars) and ZHER2-BNC/LP complex (black bars). The fluorescence of cells stained with EthD-1 was analyzed using a
flow cytometer. Cell survival rates were calculated by subtracting the dead cell counts from the total cell counts.













Figure 6 Quantification of RNAi (black bars) and cell survival rates (gray bars) of HER2-positive SKBR3 (A) and HER2-negative HeLa
(B) cells treated by negative siRNA combined with RNAiMAX, LPs and ZHER2-BNC/LP complex (final conc. 25 nM as siRNA).
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(final conc. 25 nM) and observed the cells using a con-
focal laser scanning microscope (CLSM) following 24
and 48 h of incubation (Figures 8A and 8B). In the case
of RNAiMAX, green fluorescence was rarely observed in
either cell, and the non-specific inhibition of GFP syn-
thesis was confirmed. In the case of LP, inhibition of
GFP synthesis was scarcely provoked after 24 h but was
confirmed after 48 h in both cells. This indicated that
LPs would bind to cells in a non-specific manner, and it
took longer to induce RNAi than with the transfection
reagent. However, ZHER2-BNC/LP had no impact on the
expression of GFP in HeLa cells, while the inhibition of
GFP synthesis was clearly confirmed in SKBR3 cells dur-
ing 48 h of incubation. Furthermore, diminished GFP
fluorescence was observed even after 24 h, indicating
that ZHER2-BNC/LP had fast-acting properties that were
equivalent to the transfection reagent. These results[%]
ZHER2-BNC/LP
SKBR3 HeLa
Figure 7 Quantification of RNAi (black bars) and cell survival rates (gr
treated by siRNA combined with ZHER2-BNC/LP (left side) and ZWT-BNdemonstrated that ZHER2-BNC/LP can stabilize siRNA
via the formulation of a complex carrier to efficiently
deliver siRNA inside specific HER2-expressing cells
through endosomal escape, which would allow RNAi to
effectively inhibit protein expression.
Discussion
Presently, various carriers delivering siRNA have been
studied and many research papers have reported using
the inhibition of GFP synthesis as a measure of RNAi. In
the present study, we succeeded in specifically delivering
siRNA to SKBR3 cells using a complex carrier of BNCs
and LPs (ZHER2-BNC/LP), and measured an 80% inhib-
ition of GFP synthesis following a 48 h period of incuba-
tion (Figure 4A; siRNA 20 nM).
In previous studies, PEI-PEG-FOL using cationic poly-
mers, cationic dextran nanogel using nanogel and AF-




ay bars) of HER2-positive SKBR3 and HER2-negative HeLa cells
C/LP (right side) (final conc. 25 nM as siRNA).
Figure 8 Fluorescence images of HER2-positive SKBR3 (A) and
HER2-negative HeLa (B) cells treated by siRNA combined with
RNAiMAX, LPs and ZHER2-BNC/LP complex (final conc. 25 nM as
siRNA). The cells were incubated for 24 and 48 h, and then observed
using a confocal laser scanning microscope. Scale bars, 50 μm.
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siRNA of 0.5 μg/ml [19], after 72 h of incubation with
a siRNA of 50 nM [20], and after 24 h of incubation
with a siRNA of 60 nM [21], respectively. Further-
more, in the case of lipoplex using cationic phospho-
lipids, LinOS/Chol and LinOS/DOPE inhibited 80% of
GFP synthesis after 48 h of incubation with a siRNA
of 15 nM [22]. The results of these studies suggest
that ZHER2-BNC/LP is effective at relatively low con-
centrations of siRNA. Additionally, since the results of
CLSM showed equal efficacy between incubations of
24 and 48 h (Figure 8A), it could be concluded that
ZHER2-BNC/LP shows a relatively early effective time
for the inhibition of GFP synthesis.
Compared to the carriers mentioned above, the greatest
advantage of ZHER2-BNC/LP is cell-specificity to target
cells. Since ZHER2-BNC/LP displays ZHER2 on the surface,
it was confirmed that ZHER2-BNC/LP delivers siRNAto HER2-expressing breast cancer cells (SKBR3), but
not to HER2-non-expressing cervical cancer cells
(HeLa) (Figures 4 and 8). Since BNC/LP complexes
can recognize receptors other than HER2 by altering
ligands displayed on the BNCs to other affibodies or
peptides, it should be possible to alter the specificity,
the conjugation of BNCs with LPs plays an important
role for the stability arising from stealth capability of
virus vector in the blood and blocking non-specific
electrostatic interaction with the cell membrane.
Since siRNA has a negative charge itself, the positively
charged materials (polymer, sugar chain and lipid) have
been commonly used for forming complexes. Therefore,
carriers often show a positive charge in total. In zeta poten-
tial, for example, since PEI-PEG-FOL, AF-AuNPs/siRNA-
PEG and LinOS/Chol and LinOS/DOPE showed 2.5 ±
0.9 mV [19], 35.7 ± 8.1 mV [21], and approximately 60 mV
[22], respectively, the carriers were usually introduced into
cells by using electrostatic interaction with a cell mem-
brane. The zeta potential of ZHER2-BNC/LP, on the other
hand, showed a negative charge, -5.1 ± 1.2 mV (Table 1).
Therefore, from the point of view of suppression of non-
specific adsorption to a cell membrane, ZHER2-BNC/LP
could be specifically introduced into HER2-expressing cells
by a cell recognition site derived from BNC.
Furthermore, cationic carriers are often modified by
polyethylene glycol (PEG) to improve stability in the
blood. However, since there is the dilemma that the sta-
bility obtained by modifying the PEG that forms hydra-
tion layers would cause a decrease in cellular dynamics
such as transfection efficiency and endosomal escape,
these carriers require well-balanced control between dis-
position and cellular dynamics [23]. With ZHER2-BNC/
LP it is not a problem, however, since there is no re-
quired modification of PEG due to a carrier having a
negative charge. Indeed, since the BNC/LP complex car-
rier is made stable by the virus envelope protein and
evaluated in vivo using mice without modification of
PEG [15], ZHER2-BNC/LP is expected to have a stability
that is similar to BNC/LP. Since the disposition plays a
significant factor in drug delivery systems, we thought
that ZHER2-BNC/LP would show promising results dur-
ing the clinical application of siRNA delivery.
One important issue for the ZHER2-BNC/LP is that the
efficiency of RNAi has not yet reached the same level of
the RNAiMAX transfection reagent found in low con-
centrations of siRNA (Figure 4A). This is because the ef-
ficiency of endosomal escape remains low as long as the
siRNA remains in the endosome. To improve the ability
of endosomal escape to ZHER2-BNC/LP, we mixed pH-
response phospholipids (DOPE) with LP. However, by
further enhancing the ability of endosomal escape,
ZHER2-BNC/LP would be expected to lead RNAi in low
concentrations, as is the case with transfection reagents.
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Although the therapeutic effect of siRNA has been highly
anticipated, its inability to specifically target cells and to
cross the cell membrane has limited its in vivo application
[1]. In this study, we succeeded in delivering and introdu-
cing siRNA into targeted breast carcinoma cells, which led
to the effective use of RNAi by using ZHER2-BNC/LP as
the carrier. Thus, in the field of nucleic acid medicine,
ZHER2-BNC/LP can be a useful carrier for siRNA delivery,
and could also become a useful tool for gene silencing and
to accomplish protein knock-down.
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